Tags

Type your tag names separated by a space and hit enter

Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Abstract

The authors conducted a nested case-control study of serum inflammatory markers and risk of symptomatic benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH (n = 676) was defined as treatment, report of 2 International Prostate Symptom Score (IPSS) values >14, or 2 increases of > or = 5 from baseline values with at least one value > or = 12. Controls (n = 683) were men who reported no BPH treatment or IPSS values >7 over the 7-year trial. Baseline serum was analyzed for C-reactive protein, tumor necrosis factor alpha (monomer), soluble tumor necrosis factor receptors I and II (sTNF-RI and sTNF-RII), interleukin 6, and interferon gamma. Controlled for age and race, a high C-reactive protein concentration was associated with increased BPH risk (for quartile 4 vs. quartile 1, odds ratio (OR) = 1.40, 95% confidence interval (CI): 1.04, 1.88); this was attenuated after control for body mass index (OR = 1.30, 95% CI: 0.95, 1.75). Low sTNF-RII and high interleukin 6 concentrations were associated with increased BPH risk (for quartile 4 vs. quartile 1, sTNF-RII: OR = 0.61, 95% CI: 0.46, 0.82; interleukin 6: OR = 1.79, 95% CI: 1.32, 2.42); these associations were only in men aged <65 years. Results suggest that systemic inflammation or lower levels of soluble receptors that bind inflammatory cytokines increase BPH risk.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Schenk, Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA. jschenk@fhcrc.org

    , , , , , ,

    Source

    American journal of epidemiology 171:5 2010 Mar 01 pg 571-82

    MeSH

    Aged
    Biomarkers
    C-Reactive Protein
    Humans
    Inflammation
    Interferon-gamma
    Interleukin-6
    Male
    Middle Aged
    Prostatic Hyperplasia
    Prostatic Neoplasms
    Receptors, Tumor Necrosis Factor
    Risk Assessment
    Risk Factors
    Tumor Necrosis Factor-alpha

    Pub Type(s)

    Journal Article
    Research Support, N.I.H., Extramural

    Language

    eng

    PubMed ID

    20142396

    Citation

    Schenk, Jeannette M., et al. "Biomarkers of Systemic Inflammation and Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial." American Journal of Epidemiology, vol. 171, no. 5, 2010, pp. 571-82.
    Schenk JM, Kristal AR, Neuhouser ML, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2010;171(5):571-82.
    Schenk, J. M., Kristal, A. R., Neuhouser, M. L., Tangen, C. M., White, E., Lin, D. W., ... Thompson, I. M. (2010). Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. American Journal of Epidemiology, 171(5), pp. 571-82. doi:10.1093/aje/kwp406.
    Schenk JM, et al. Biomarkers of Systemic Inflammation and Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial. Am J Epidemiol. 2010 Mar 1;171(5):571-82. PubMed PMID: 20142396.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. AU - Schenk,Jeannette M, AU - Kristal,Alan R, AU - Neuhouser,Marian L, AU - Tangen,Catherine M, AU - White,Emily, AU - Lin,Daniel W, AU - Kratz,Mario, AU - Thompson,Ian M, Y1 - 2010/02/08/ PY - 2010/2/10/entrez PY - 2010/2/10/pubmed PY - 2010/4/1/medline SP - 571 EP - 82 JF - American journal of epidemiology JO - Am. J. Epidemiol. VL - 171 IS - 5 N2 - The authors conducted a nested case-control study of serum inflammatory markers and risk of symptomatic benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH (n = 676) was defined as treatment, report of 2 International Prostate Symptom Score (IPSS) values >14, or 2 increases of > or = 5 from baseline values with at least one value > or = 12. Controls (n = 683) were men who reported no BPH treatment or IPSS values >7 over the 7-year trial. Baseline serum was analyzed for C-reactive protein, tumor necrosis factor alpha (monomer), soluble tumor necrosis factor receptors I and II (sTNF-RI and sTNF-RII), interleukin 6, and interferon gamma. Controlled for age and race, a high C-reactive protein concentration was associated with increased BPH risk (for quartile 4 vs. quartile 1, odds ratio (OR) = 1.40, 95% confidence interval (CI): 1.04, 1.88); this was attenuated after control for body mass index (OR = 1.30, 95% CI: 0.95, 1.75). Low sTNF-RII and high interleukin 6 concentrations were associated with increased BPH risk (for quartile 4 vs. quartile 1, sTNF-RII: OR = 0.61, 95% CI: 0.46, 0.82; interleukin 6: OR = 1.79, 95% CI: 1.32, 2.42); these associations were only in men aged <65 years. Results suggest that systemic inflammation or lower levels of soluble receptors that bind inflammatory cytokines increase BPH risk. SN - 1476-6256 UR - https://www.unboundmedicine.com/medline/citation/20142396/Biomarkers_of_systemic_inflammation_and_risk_of_incident_symptomatic_benign_prostatic_hyperplasia:_results_from_the_prostate_cancer_prevention_trial_ L2 - https://academic.oup.com/aje/article-lookup/doi/10.1093/aje/kwp406 DB - PRIME DP - Unbound Medicine ER -